Do Han Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Do Han Kim has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Donghyun Ko
Department of Medicine, Bridgeport Hospital Yale New Haven Health Bridgeport Connecticut USA
7 shared publications Frank J. Lukens
Division of Gastroenterology and Hepatology, Mayo Clinic Florida, Jacksonville, FL, USA
5 shared publications- Pedro Palacios Argueta
Gastroenterology and Hepatology Department, Mayo Clinic Florida, Jacksonville, FL, USA
5 shared publications Donghyun Ko
Division of Health Care Sciences, Dresden International University, Dresden, Germany
4 shared publications- Paul Thomas Kröner
Department of Gastroenterology, Riverside Health System, Newport News, VA, USA
4 shared publications - Frank J. Lukens
Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL
3 shared publications
Latest Publications
- 18 October 2026
- Published by Wiley in Journal of Gastroenterology and Hepatology
Impact of Physical Activity on Cardiovascular Outcomes in Metabolic Dysfunction‐Associated Steatotic Liver Disease
Aim: We investigated whether accelerometer‐assessed moderate‐to‐vigorous physical activity (MVPA) is associated with cardiovascular mortality among individuals with metabolic dysfunction‐associated steatotic liver disease (MASLD) in the United States. Methods: We performed a longitudinal analysis using the 2003–2006 US National Health and Nutrition Examination Survey data among adults, with mortality follow‐up through December 2019. We defined MASLD primarily using the Hepatic Steatosis Index (HSI), followed by current cardiometabolic criteria; we used the US Fatty Liver Index (USFLI) in sensitivity analyses. We classified accelerometer‐assessed PA as MVPA, total PA, and sedentary behavior. Results: Among 2785 individuals with HSI‐defined MASLD, 584 deaths occurred, including 198 cardiovascular deaths, over a median follow‐up of 14.7 years. A higher level of PA is associated with a more favorable predicted cardiovascular risk profile at baseline. Among individuals with MASLD, increasing MVPA was nonlinearly associated with reduced all‐cause mortality in a multivariable model (hazard ratio [HR]: 0.80, 95% CI: 0.71–0.91 per 10‐min increase; P for trend < 0.001). Furthermore, higher MVPA was nonlinearly associated with a lower risk of cardiovascular mortality in MASLD (HR: 0.72, 95% CI: 0.53–0.99 per 10‐min increase; P for trend = 0.009). Although higher total PA was also associated with reduced mortality, the point estimate was substantially weaker than that observed for MVPA. Sensitivity analyses using the USFLI definition showed directionally similar but attenuated associations. Increased sedentary behavior did not impact mortality in the MASLD group. Conclusions: Higher MVPA is nonlinearly associated with cardiovascular mortality in individuals with MASLD.
- 18 October 2026
- Published by Wiley in Journal of Gastroenterology and Hepatology
Impact of Physical Activity on Cardiovascular Outcomes in Metabolic Dysfunction‐Associated Steatotic Liver Disease
Aim: We investigated whether accelerometer‐assessed moderate‐to‐vigorous physical activity (MVPA) is associated with cardiovascular mortality among individuals with metabolic dysfunction‐associated steatotic liver disease (MASLD) in the United States. Methods: We performed a longitudinal analysis using the 2003–2006 US National Health and Nutrition Examination Survey data among adults, with mortality follow‐up through December 2019. We defined MASLD primarily using the Hepatic Steatosis Index (HSI), followed by current cardiometabolic criteria; we used the US Fatty Liver Index (USFLI) in sensitivity analyses. We classified accelerometer‐assessed PA as MVPA, total PA, and sedentary behavior. Results: Among 2785 individuals with HSI‐defined MASLD, 584 deaths occurred, including 198 cardiovascular deaths, over a median follow‐up of 14.7 years. A higher level of PA is associated with a more favorable predicted cardiovascular risk profile at baseline. Among individuals with MASLD, increasing MVPA was nonlinearly associated with reduced all‐cause mortality in a multivariable model (hazard ratio [HR]: 0.80, 95% CI: 0.71–0.91 per 10‐min increase; P for trend < 0.001). Furthermore, higher MVPA was nonlinearly associated with a lower risk of cardiovascular mortality in MASLD (HR: 0.72, 95% CI: 0.53–0.99 per 10‐min increase; P for trend = 0.009). Although higher total PA was also associated with reduced mortality, the point estimate was substantially weaker than that observed for MVPA. Sensitivity analyses using the USFLI definition showed directionally similar but attenuated associations. Increased sedentary behavior did not impact mortality in the MASLD group. Conclusions: Higher MVPA is nonlinearly associated with cardiovascular mortality in individuals with MASLD.
- 15 April 2026
- Published by Springer Nature in European Geriatric Medicine
- Vol. 17 (3) , 1569-1578
Risk of 30-day all-cause mortality in octogenarians with non-variceal upper gastrointestinal bleeding: a multinational analysis
Studies show declining non-variceal upper gastrointestinal bleeding (NVUGIB) incidence and hospitalization, likely due to novel pharmacological and endoscopic therapies. However, data on mortality and outcomes in octogenarians with NVUGIB remain limited. We conducted a retrospective cohort study using the TriNetX platform, identifying adults NVUGIB between January 1, 2014, and May 18, 2025. Patients with gastroesophageal variceal bleeding were excluded. Two age cohorts (> 80 years and 18-65 years) were 1:1 propensity matched according to sex, demographics, comorbidities, and medications. The primary outcome was risk of all-cause mortality. Secondary outcomes included in-hospital and procedure-related outcomes. Cox-proportional hazards models estimated hazard ratios (HR) with 95% confidence intervals (CIs). 117,695 octogenarians (mean [SD] age, 81.4 [5.3] year; 59,524 [50.6%] female) were matched with 117,695 patients < 65 years (mean [SD] age, 44.9 [13.6] year; 60,044 [51.0%] female). The octogenarian cohort had significantly higher all-cause mortality (HR, 2.73; 95% CI 2.60-2.87), acute kidney injury (HR, 1.61; 95% CI 1.56-1.66), mechanical ventilation (HR, 1.17; 95% CI 1.12-1.23), hypovolemic shock (HR, 1.54; 95% CI 1.40-1.70), and intensive care unit admission (HR, 1.10; 95% CI 1.06-1.13) compared to those aged under 65 years. Subgroup analysis comparing the timing of endoscopy and its effect on mortality showed increased all-cause mortality in octogenarians with NVUGIB and early endoscopy (HR, 2.04; 95% CI 1.81-2.30). Through this multicenter retrospective study, we demonstrate that octogenarians with NVUGIB have a 2.7-fold higher risk of all-cause mortality. This study emphasizes the importance of early diagnosis, aggressive management, and risk stratification to improve outcomes in this population.
- 15 April 2026
- Published by Springer Nature in European Geriatric Medicine
- Vol. 17 (3) , 1569-1578
Risk of 30-day all-cause mortality in octogenarians with non-variceal upper gastrointestinal bleeding: a multinational analysis
Studies show declining non-variceal upper gastrointestinal bleeding (NVUGIB) incidence and hospitalization, likely due to novel pharmacological and endoscopic therapies. However, data on mortality and outcomes in octogenarians with NVUGIB remain limited. We conducted a retrospective cohort study using the TriNetX platform, identifying adults NVUGIB between January 1, 2014, and May 18, 2025. Patients with gastroesophageal variceal bleeding were excluded. Two age cohorts (> 80 years and 18-65 years) were 1:1 propensity matched according to sex, demographics, comorbidities, and medications. The primary outcome was risk of all-cause mortality. Secondary outcomes included in-hospital and procedure-related outcomes. Cox-proportional hazards models estimated hazard ratios (HR) with 95% confidence intervals (CIs). 117,695 octogenarians (mean [SD] age, 81.4 [5.3] year; 59,524 [50.6%] female) were matched with 117,695 patients < 65 years (mean [SD] age, 44.9 [13.6] year; 60,044 [51.0%] female). The octogenarian cohort had significantly higher all-cause mortality (HR, 2.73; 95% CI 2.60-2.87), acute kidney injury (HR, 1.61; 95% CI 1.56-1.66), mechanical ventilation (HR, 1.17; 95% CI 1.12-1.23), hypovolemic shock (HR, 1.54; 95% CI 1.40-1.70), and intensive care unit admission (HR, 1.10; 95% CI 1.06-1.13) compared to those aged under 65 years. Subgroup analysis comparing the timing of endoscopy and its effect on mortality showed increased all-cause mortality in octogenarians with NVUGIB and early endoscopy (HR, 2.04; 95% CI 1.81-2.30). Through this multicenter retrospective study, we demonstrate that octogenarians with NVUGIB have a 2.7-fold higher risk of all-cause mortality. This study emphasizes the importance of early diagnosis, aggressive management, and risk stratification to improve outcomes in this population.
- 18 March 2026
- Published by Elsevier in Pancreatology
Reply to letters to the editor regarding the use of aspirin and mortality due to acute pancreatitis
- 18 March 2026
- Published by Elsevier in Pancreatology
Reply to letters to the editor regarding the use of aspirin and mortality due to acute pancreatitis
- 27 December 2025
- Published by Wiley in Liver International
- Vol. 46 (2) , e70490
SGLT ‐2 Inhibitors Are Associated With Lower Mortality and Decompensation in Patients With MASH Cirrhosis and Type 2 Diabetes
Introduction: Metabolic dysfunction‐associated steatotic liver disease (MASLD) and steatohepatitis (MASH) represent a spectrum of liver conditions that can gradually progress to cirrhosis. Sodium‐glucose co‐transporter‐2 (SGLT‐2) inhibitors have shown benefits in reducing hepatic steatosis and liver‐related events in MASLD. This study aims to assess whether SGLT‐2 inhibitors are associated with a reduced risk of all‐cause mortality and disease‐specific outcomes in patients with MASH cirrhosis and type 2 diabetes (T2D). Methods: A retrospective cohort study was performed using TriNetX. Patients with T2D and MASH cirrhosis on SGLT‐2 inhibitors were matched 1:1 with other glucose‐lowering drugs (oGLDs) based on demographics, comorbidities and medications. Primary outcomes included all‐cause mortality, hepatic decompensation and major adverse liver outcomes (MALO). Cox‐proportional hazards models were used to estimate hazard ratios (HRs) with 95% confidence interval (CI). Results: A total of 51 427 patients with MASH cirrhosis and T2D were identified, of which 6833 (13.28%) were on SGLT‐2 inhibitors. Patients on SGLT‐2 inhibitors ( n = 6449, mean age 63.7 years, 52.9% female) were matched with 6449 individuals (mean age 63.9 years, 53.5% female) on oGLDs. The SGLT‐2 inhibitors cohort had statistically significantly lower risk of all‐cause mortality (HR: 0.58, 95% CI: 0.53–0.63), hepatic decompensation (HR: 0.85, 95% CI: 0.81–0.90) and MALO (HR: 0.88, 95% CI: 0.83–0.93). Conclusion: SGLT‐2 inhibitors are associated with a reduced risk of all‐cause mortality in patients with MASH cirrhosis and T2DM, which may be partly attributable to a lower risk of hepatic decompensation and subsequent events. Further studies are warranted as SGLT‐2 inhibitors may serve as an adjunctive therapy for patients with MASH cirrhosis.
- 27 December 2025
- Published by Wiley in Liver International
- Vol. 46 (2) , e70490
SGLT ‐2 Inhibitors Are Associated With Lower Mortality and Decompensation in Patients With MASH Cirrhosis and Type 2 Diabetes
Introduction: Metabolic dysfunction‐associated steatotic liver disease (MASLD) and steatohepatitis (MASH) represent a spectrum of liver conditions that can gradually progress to cirrhosis. Sodium‐glucose co‐transporter‐2 (SGLT‐2) inhibitors have shown benefits in reducing hepatic steatosis and liver‐related events in MASLD. This study aims to assess whether SGLT‐2 inhibitors are associated with a reduced risk of all‐cause mortality and disease‐specific outcomes in patients with MASH cirrhosis and type 2 diabetes (T2D). Methods: A retrospective cohort study was performed using TriNetX. Patients with T2D and MASH cirrhosis on SGLT‐2 inhibitors were matched 1:1 with other glucose‐lowering drugs (oGLDs) based on demographics, comorbidities and medications. Primary outcomes included all‐cause mortality, hepatic decompensation and major adverse liver outcomes (MALO). Cox‐proportional hazards models were used to estimate hazard ratios (HRs) with 95% confidence interval (CI). Results: A total of 51 427 patients with MASH cirrhosis and T2D were identified, of which 6833 (13.28%) were on SGLT‐2 inhibitors. Patients on SGLT‐2 inhibitors ( n = 6449, mean age 63.7 years, 52.9% female) were matched with 6449 individuals (mean age 63.9 years, 53.5% female) on oGLDs. The SGLT‐2 inhibitors cohort had statistically significantly lower risk of all‐cause mortality (HR: 0.58, 95% CI: 0.53–0.63), hepatic decompensation (HR: 0.85, 95% CI: 0.81–0.90) and MALO (HR: 0.88, 95% CI: 0.83–0.93). Conclusion: SGLT‐2 inhibitors are associated with a reduced risk of all‐cause mortality in patients with MASH cirrhosis and T2DM, which may be partly attributable to a lower risk of hepatic decompensation and subsequent events. Further studies are warranted as SGLT‐2 inhibitors may serve as an adjunctive therapy for patients with MASH cirrhosis.
- Open Access
- 21 October 2025
- Published by MDPI AG in Gastroenterology Insights
- Vol. 16 (4) , 40
African and Hispanic Americans Have Higher Healthcare-Related Burden Without Higher Mortality When Admitted with Acute Diverticulitis
Background: Health disparities between racial groups continue to exist. There is a paucity of data regarding presentation severity for acute diverticulitis (AD) and surgery need by race. This study’s aim was to evaluate outcomes of AD in United States racial groups. Methods: A retrospective cohort study was performed using the 2016–2019 National Inpatient Sample of adult patients discharged for AD. Patients were classified into six racial and ethnic groups: Caucasian, African American (AA), Hispanic, Asian, Native American (NA), and other. Multivariate regression analysis adjusted for patient and hospital characteristics was performed for primary and secondary outcomes. Results: A total of 647,119 admissions with acute diverticulitis (AD) were identified. Most patients were Caucasian (about three-quarters), followed by Hispanics (11%), AA (9%), Asians (1%), Native Americans (<1%), and other (2%). Minority groups were generally younger than Caucasians and less likely to undergo colonoscopy or surgical procedures such as partial or total colectomy. In the multivariable analysis, both Hispanics and AA were less likely to present with complicated diverticulitis. Despite this, their hospitalizations were associated with higher overall charges and costs. No significant differences were found across groups in terms of inpatient mortality or the need for percutaneous abscess drainage. Conclusions: Hispanic and AA have higher healthcare- related charges and costs compared to Caucasians when admitted with AD. Further studies are needed to understand the healthcare-related spending variations seen in these groups despite them often having less complicated AD.
- 21 October 2025
- Published by MDPI AG in Gastroenterology Insights
- Vol. 16 (4) , 40
Open AccessAfrican and Hispanic Americans Have Higher Healthcare-Related Burden Without Higher Mortality When Admitted with Acute Diverticulitis
Background: Health disparities between racial groups continue to exist. There is a paucity of data regarding presentation severity for acute diverticulitis (AD) and surgery need by race. This study’s aim was to evaluate outcomes of AD in United States racial groups. Methods: A retrospective cohort study was performed using the 2016–2019 National Inpatient Sample of adult patients discharged for AD. Patients were classified into six racial and ethnic groups: Caucasian, African American (AA), Hispanic, Asian, Native American (NA), and other. Multivariate regression analysis adjusted for patient and hospital characteristics was performed for primary and secondary outcomes. Results: A total of 647,119 admissions with acute diverticulitis (AD) were identified. Most patients were Caucasian (about three-quarters), followed by Hispanics (11%), AA (9%), Asians (1%), Native Americans (<1%), and other (2%). Minority groups were generally younger than Caucasians and less likely to undergo colonoscopy or surgical procedures such as partial or total colectomy. In the multivariable analysis, both Hispanics and AA were less likely to present with complicated diverticulitis. Despite this, their hospitalizations were associated with higher overall charges and costs. No significant differences were found across groups in terms of inpatient mortality or the need for percutaneous abscess drainage. Conclusions: Hispanic and AA have higher healthcare- related charges and costs compared to Caucasians when admitted with AD. Further studies are needed to understand the healthcare-related spending variations seen in these groups despite them often having less complicated AD.
- 25 September 2025
- Published by Elsevier in Pancreatology
- Vol. 25 (7) , 1080-1085
Low-dose aspirin use is associated with reduced 30- and 90-day mortality and overall improved outcomes in patients with acute pancreatitis: A multinational multicenter analysis
- 25 September 2025
- Published by Elsevier in Pancreatology
- Vol. 25 (7) , 1080-1085
Low-dose aspirin use is associated with reduced 30- and 90-day mortality and overall improved outcomes in patients with acute pancreatitis: A multinational multicenter analysis
- 24 May 2025
- Published by Elsevier in Pancreatology
- Vol. 25 (4) , 508-515
Disproportionately rising mortality rates of alcohol-associated acute Pancreatitis: Analysis from centers for Disease Control and prevention database (2011–2020)
- 24 May 2025
- Published by Elsevier in Pancreatology
- Vol. 25 (4) , 508-515
Disproportionately rising mortality rates of alcohol-associated acute Pancreatitis: Analysis from centers for Disease Control and prevention database (2011–2020)
- 13 May 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (2) , 424-431
Glucagon-Like Peptide-1 Receptor Agonists Use Does Not Increase the Risk for Acute Pancreatitis and Is Associated With Lower Complications in Patients With Type 2 Diabetes Who Develop Acute Pancreatitis: A Multicenter Analysis
INTRODUCTION: Type 2 diabetes mellitus (T2DM) can lead to structural pancreatic changes potentially predisposing to acute pancreatitis (AP), increasing morbidity and mortality. Scarce data exist on the outcomes of AP in patients with T2DM who are taking glucagon-like peptide-1 receptor agonists (GLP-1 RAs). The study aim was to evaluate AP outcome and all-cause mortality in patients with T2DM using GLP-1 RAs. METHODS: A retrospective cohort study was performed using population-based data from the TriNetX platform. Patients with T2DM receiving GLP-1 RAs drugs (semaglutide, liraglutide, dulaglutide, and tirzepatide) between January 1, 2015, and October 31, 2023, were included. This patient cohort was matched with patients with T2DM who did not receive GLP-1 RAs according to age, demographics, comorbidities, and medication by using 1:1 propensity matching. To avoid confounding, etiologies of AP including alcohol-induced, trauma, biliary, class Ia drug-induced, hypertriglyceridemia, and postendoscopic retrograde cholangiopancreatography were excluded from both cohorts. Primary outcomes were risk of developing AP, need for parenteral nutrition, systemic complications (sepsis, systemic inflammatory response syndrome, shock, mechanical ventilation, acute kidney injury), and local pancreatic complications. The secondary outcome was all-cause mortality. Cox proportional hazards models were used to estimate hazard ratios (HRs). RESULTS: A total of 740,370 patients with T2DM were identified with 29,423 on GLP-1 RAs; 20,459 of those 29,423 (mean [SD] age, 58.1 [11.9] years; 10,190 [49.85%] female) were matched with 20,459 individuals (mean [SD] age, 57.5 [13.9] years; 10,301 [50.35%] female) who did not take GLP-1 RAs. The GLP-1 RAs group had lower risk of complicated pancreatitis (HR 0.32; 95% confidence interval [CI] 0.14–0.74), parenteral nutrition needs (HR 0.28; 95% CI 0.09–0.83), sepsis (HR 0.71; 95% CI 0.59–0.84), acute kidney injury (HR 0.54; 95% CI 0.49–0.60), shock (HR 0.52; 95% CI 0.36–0.75), and mechanical ventilation support during admission (HR 0.23; 95% CI 0.16–0.33) compared with the non-GLP-1 RAs group. In addition, all-cause mortality was decreased in the GLP-1 agonist group compared with the non-GLP-1 agonist group (HR 0.45; 95% CI 0.41–0.49). Important to note that the GLP-1 RAs group had a tendency of lower risk of uncomplicated pancreatitis (HR 0.71; 95% CI 0.49–1.01) but without statistically significant result. No difference was found between the groups in risk of developing systemic inflammatory response syndrome if it occurs. DISCUSSION: GLP-1 RAs use does not increase AP risk is associated with lower complications in those who developed AP and linked with lower all-cause mortality in patients with T2DM. Prospective studies are needed to determine the mechanisms behind these findings.
- 13 May 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (2) , 424-431
Glucagon-Like Peptide-1 Receptor Agonists Use Does Not Increase the Risk for Acute Pancreatitis and Is Associated With Lower Complications in Patients With Type 2 Diabetes Who Develop Acute Pancreatitis: A Multicenter Analysis
INTRODUCTION: Type 2 diabetes mellitus (T2DM) can lead to structural pancreatic changes potentially predisposing to acute pancreatitis (AP), increasing morbidity and mortality. Scarce data exist on the outcomes of AP in patients with T2DM who are taking glucagon-like peptide-1 receptor agonists (GLP-1 RAs). The study aim was to evaluate AP outcome and all-cause mortality in patients with T2DM using GLP-1 RAs. METHODS: A retrospective cohort study was performed using population-based data from the TriNetX platform. Patients with T2DM receiving GLP-1 RAs drugs (semaglutide, liraglutide, dulaglutide, and tirzepatide) between January 1, 2015, and October 31, 2023, were included. This patient cohort was matched with patients with T2DM who did not receive GLP-1 RAs according to age, demographics, comorbidities, and medication by using 1:1 propensity matching. To avoid confounding, etiologies of AP including alcohol-induced, trauma, biliary, class Ia drug-induced, hypertriglyceridemia, and postendoscopic retrograde cholangiopancreatography were excluded from both cohorts. Primary outcomes were risk of developing AP, need for parenteral nutrition, systemic complications (sepsis, systemic inflammatory response syndrome, shock, mechanical ventilation, acute kidney injury), and local pancreatic complications. The secondary outcome was all-cause mortality. Cox proportional hazards models were used to estimate hazard ratios (HRs). RESULTS: A total of 740,370 patients with T2DM were identified with 29,423 on GLP-1 RAs; 20,459 of those 29,423 (mean [SD] age, 58.1 [11.9] years; 10,190 [49.85%] female) were matched with 20,459 individuals (mean [SD] age, 57.5 [13.9] years; 10,301 [50.35%] female) who did not take GLP-1 RAs. The GLP-1 RAs group had lower risk of complicated pancreatitis (HR 0.32; 95% confidence interval [CI] 0.14–0.74), parenteral nutrition needs (HR 0.28; 95% CI 0.09–0.83), sepsis (HR 0.71; 95% CI 0.59–0.84), acute kidney injury (HR 0.54; 95% CI 0.49–0.60), shock (HR 0.52; 95% CI 0.36–0.75), and mechanical ventilation support during admission (HR 0.23; 95% CI 0.16–0.33) compared with the non-GLP-1 RAs group. In addition, all-cause mortality was decreased in the GLP-1 agonist group compared with the non-GLP-1 agonist group (HR 0.45; 95% CI 0.41–0.49). Important to note that the GLP-1 RAs group had a tendency of lower risk of uncomplicated pancreatitis (HR 0.71; 95% CI 0.49–1.01) but without statistically significant result. No difference was found between the groups in risk of developing systemic inflammatory response syndrome if it occurs. DISCUSSION: GLP-1 RAs use does not increase AP risk is associated with lower complications in those who developed AP and linked with lower all-cause mortality in patients with T2DM. Prospective studies are needed to determine the mechanisms behind these findings.
- 30 April 2025
- Published by Elsevier in The American Journal of Medicine
- Vol. 138 (9) , 1238-1247.e4
Longitudinal Clinical Outcomes and Mortality from Steatotic Liver Disease: A Meta-Analysis
- 30 April 2025
- Published by Elsevier in The American Journal of Medicine
- Vol. 138 (9) , 1238-1247.e4
Longitudinal Clinical Outcomes and Mortality from Steatotic Liver Disease: A Meta-Analysis
- 17 October 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (4) , 702
Gastrointestinal Xanthomas and Ichthyosis: A Mild Phenotype of CHILD Syndrome (NSDHL Gene Mutation)
An abstract is unavailable. This article is available as a PDF only.
- 17 October 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (4) , 702
Gastrointestinal Xanthomas and Ichthyosis: A Mild Phenotype of CHILD Syndrome (NSDHL Gene Mutation)
An abstract is unavailable. This article is available as a PDF only.